NEW YORK (GenomeWeb News) — NimbleGen will help Upstream Biosciences validate biomarkers, Upstream said today.
 
Under the agreement, NimbleGen will provide lab services including its whole-genome chromatin immunoprecipitation arrays to validate in silico binding-site predictions, Upstream said.
 
Upstream said it has filed five patents that would cover the use of genetic variations in certain regions that mark "various" cancers.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

May
01
Sponsored by
Horizon Discovery

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

May
08
Sponsored by
Dovetail Genomics

This webinar will discuss a proximity ligation-based method for studying structural variation in formalin-fixed paraffin-embedded (FFPE) tissue.